In the multivariate analysis, which included performance status, when analyzing variables including type of chemotherapy (palliative vs. other), cancer stage, and EGFR mutation status, cancer stage (II, IIIC or IV) was the only factor that significantly influenced the concordance rate between the WFO (‘Recommended’ only) and MDT-determined regimens (OR: 0.092, 95% CI: 0.030–0.282) and between the WFO (‘For consideration’)- and MDT-determined regimens (OR: 0.117, 95% CI: 0.014–0.994). The gene discussed is EGFR; the disease is cancer.